This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

In A Nutshell A new animal study found that SNAC, the absorption-boosting additive in Rybelsus (oral semaglutide), was linked ...

It’s worth the weight — loss, that is. Despite their blockbuster popularity, GLP-1 medications come with a handful of side ...

Healthcare industry stocks are traditionally good hedges against technology and other growth stocks, because they tend to ...

CEO Sarah Howell talked with Proactive about the company’s second-half performance and its strategic priorities heading into ...

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.

Semaglutide is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus and chronic weight management.

The prescription-only medicine is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

The federal government has expanded its drug price negotiation program for seniors in Michigan and beyond, adding more than a ...

Legal battle between Novo Nordisk and US compounding pharmacy Hims & Hers has fizzled after regulator intervention ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and peripheral artery disease (PAD), potentially adding yet another indication ...

The federal government has expanded its drug price negotiation program for seniors, adding more than a dozen high-cost medicines ...